Cerebral Vasospasm After Subarachnoid Hemorrhage Guidelines

Updated: Sep 12, 2022
  • Author: William W Ashley, Jr, MD, PhD, MBA; Chief Editor: Brian H Kopell, MD  more...
  • Print
Guidelines

AHA/ASA Guidelines for Post-aSAH Cerebral Vasospasm

In 2012, the American Heart Association (AHA) and the American Stroke Association (ASA) published updated evidence-based guidelines on the comprehensive management of aneurysmal subarachnoid hemorrhage (aSAH), including the management of cerebral vasospasm and delayed cerebral ischemia (DCI). [13]  These guidelines were endorsed by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Society of NeuroInterventional Surgery.

The 2012 AHA/ASA recommendations for management of cerebral vasospasm and DCI after aSAH are as follows [13] :

  • Oral nimodipine should be administered to all patients with aSAH (class I; level of evidence, A) - It should be noted that this agent has been shown to improve neurologic outcomes but not cerebral vasospasm; the value of other calcium antagonists, whether administered orally or intravenously, remains uncertain
  • Maintenance of euvolemia and normal circulating blood volume is recommended to prevent DCI (class I; level of evidence, B) - Revised recommendation from previous guidelines
  • Prophylactic hypervolemia or balloon angioplasty before the development of angiographic spasm is not recommended(class III; level of evidence, B) - New recommendation
  • Transcranial Doppler is reasonable to monitor for the development of arterial vasospasm (class IIa; level of evidence, B) - New recommendation
  • Perfusion imaging with computed tomography (CT) or magnetic resonance imaging (MRI) can be useful to identify regions of potential brain ischemia (class IIa; level of evidence, B) - New recommendation
  • Induction of hypertension is recommended for patients with DCI unless blood pressure is elevated at baseline or cardiac status precludes it (class I; level of evidence, B) - Revised recommendation from previous guidelines
  • Cerebral angioplasty and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to hypertensive therapy (class IIa; level of evidence, B) -  Revised recommendation from previous guidelines